The company pioneers non-viral, precision-genome engineered, tumor-specific T-cell therapies for cancer patients, identifying neo-epitopes that serve as private mutations for each patient's cancer and engineering autologous T cells to target and kill tumors expressing these neo-antigens. Their vision is to create potentially curative T cell therapies for solid cancers tailored to each patient. The company values teamwork, humility, and kindness, and seeks individuals who share their values and desire to turn ideas into realities. PACT Pharma offers a competitive compensation and benefits package, including participation in the aggressive growth of the company in the form of stock option grants.